Viking Therapeutics Quarterly Balance Sheets Chart
Quarterly
|
Annual
Viking Therapeutics Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||||||||||||||||||||||||
| current assets: | ||||||||||||||||||||||||||||||||||||||||||
| cash and cash equivalents | 33,880,000 | 37,940,000 | 26,676,000 | 50,347,000 | 43,915,000 | 195,579,000 | 55,516,000 | 37,185,000 | 69,519,000 | 18,362,000 | 36,632,000 | 29,408,000 | 16,226,000 | 12,454,000 | 26,371,000 | 11,264,000 | 8,829,000 | 16,805,000 | 29,117,000 | 3,870,000 | 18,790,000 | 15,260,000 | 8,377,000 | 30,952,000 | 19,123,000 | 14,343,000 | 24,779,000 | 169,506,000 | 34,610,000 | 36,356,000 | 8,988,478 | 2,568,063 | 3,393,651 | 4,359,046 | 3,075,502 | 3,054,892 | 5,159,930 | 3,958,763 | 768,550 | 2,140,115 | 9,497,200 | |
| short-term investments – available-for-sale | 773,844,000 | 813,918,000 | 875,936,000 | 880,093,000 | 898,348,000 | 767,397,000 | 306,563,000 | 339,056,000 | 323,401,000 | 117,302,000 | ||||||||||||||||||||||||||||||||
| prepaid clinical trial and preclinical study costs | 16,478,000 | 13,300,000 | 3,476,000 | 4,476,000 | 3,323,000 | 2,716,000 | 2,624,000 | 4,389,000 | 5,491,000 | 9,878,000 | 8,144,000 | 9,167,000 | 9,859,000 | 8,012,000 | 7,806,000 | 7,235,000 | 8,254,000 | 7,559,000 | 7,276,000 | 7,120,000 | 6,702,000 | 6,738,000 | 7,458,000 | 612,000 | 343,000 | 168,000 | 335,000 | 1,847,000 | 1,499,000 | 1,014,000 | ||||||||||||
| prepaid expenses and other current assets | 2,815,000 | 865,000 | 1,128,000 | 1,733,000 | 138,000 | 643,000 | 2,522,000 | 670,000 | 960,000 | 3,926,000 | 3,411,000 | 956,000 | 1,087,000 | 388,000 | 619,000 | 915,000 | 1,150,000 | 625,000 | 442,000 | 710,000 | 914,000 | 547,000 | 405,000 | 572,000 | 665,000 | 251,000 | 278,000 | 607,000 | 593,000 | 249,000 | 388,969 | 340,121 | 447,932 | 177,451 | 824,269 | 1,005,471 | 1,113,696 | 909,895 | 1,097,599 | 1,442,629 | 610,198 | 33,391 |
| total current assets | 827,017,000 | 866,023,000 | 907,216,000 | 936,649,000 | 945,724,000 | 966,335,000 | 367,225,000 | 381,300,000 | 399,371,000 | 149,468,000 | 167,040,000 | 165,146,000 | 179,863,000 | 193,299,000 | 210,528,000 | 224,285,000 | 237,662,000 | 249,863,000 | 256,104,000 | 263,134,000 | 270,618,000 | 276,446,000 | 283,501,000 | 289,256,000 | 293,644,000 | 299,137,000 | 302,133,000 | 306,616,000 | 144,258,000 | 78,731,000 | 21,851,798 | 11,525,074 | 14,264,002 | 14,673,917 | 13,974,829 | 15,623,313 | 18,310,165 | 12,161,521 | 15,201,648 | 18,932,251 | 22,269,649 | 360,398 |
| right-of-use assets | 780,000 | 892,000 | 1,003,000 | 1,113,000 | 977,000 | 1,052,000 | 1,126,000 | 1,200,000 | 1,273,000 | 1,346,000 | 1,418,000 | 1,489,000 | 1,560,000 | 1,632,000 | 25,000 | 101,000 | 176,000 | 249,000 | 321,000 | 392,000 | 462,000 | 530,000 | 598,000 | 664,000 | 730,000 | 794,000 | ||||||||||||||||
| deferred financing costs | 8,000 | 32,000 | 56,000 | 80,000 | 105,000 | 98,000 | 106,000 | 130,000 | 16,000 | 48,000 | 38,000 | 15,000 | 52,000 | 64,000 | 88,000 | 7,000 | 27,000 | |||||||||||||||||||||||||
| deposits | 46,000 | 46,000 | 46,000 | 46,000 | 33,000 | 33,000 | 33,000 | 33,000 | 33,000 | 33,000 | 33,000 | 33,000 | 33,000 | 33,000 | 33,000 | 29,000 | 29,000 | 29,000 | 29,000 | 29,000 | 29,000 | 29,000 | 29,000 | 29,000 | 39,341 | 39,341 | 39,341 | 39,341 | 80,000 | 80,000 | 80,000 | 80,000 | ||||||||||
| total assets | 827,851,000 | 866,993,000 | 908,321,000 | 937,888,000 | 946,839,000 | 967,518,000 | 368,490,000 | 382,663,000 | 400,693,000 | 150,895,000 | 168,529,000 | 166,683,000 | 181,508,000 | 195,028,000 | 210,662,000 | 224,474,000 | 237,845,000 | 250,139,000 | 256,502,000 | 263,623,000 | 271,198,000 | 277,104,000 | 284,256,000 | 290,122,000 | 294,493,000 | 300,080,000 | 302,312,000 | 306,796,000 | 144,468,000 | 78,971,000 | 22,121,411 | 11,839,444 | 14,320,911 | 15,152,607 | 14,535,708 | 16,317,693 | 18,549,007 | 12,756,902 | 15,439,103 | 19,012,251 | 22,269,649 | 2,769,322 |
| liabilities and stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||||||||||||||||||||||||
| accounts payable | 5,494,000 | 7,702,000 | 9,813,000 | 254,000 | 11,090,000 | 5,225,000 | 7,512,000 | 5,711,000 | 5,611,000 | 3,799,000 | 8,529,000 | 3,142,000 | 6,104,000 | 3,119,000 | 1,444,000 | 2,852,000 | 4,210,000 | 4,848,000 | 3,988,000 | 2,756,000 | 3,209,000 | 3,098,000 | 2,431,000 | 2,095,000 | 1,870,000 | 1,676,000 | 959,000 | 1,215,000 | 1,493,000 | 658,000 | 1,529,935 | 1,555,472 | 1,304,711 | 1,726,824 | 1,203,888 | 881,311 | 1,206,384 | 1,172,351 | 592,414 | 401,672 | 1,008,277 | 1,879,414 |
| other accrued liabilities | 26,018,000 | 11,373,000 | 17,111,000 | 24,951,000 | 13,669,000 | 27,220,000 | 11,299,000 | 7,375,000 | 7,553,000 | 11,541,000 | 13,114,000 | 10,620,000 | 8,522,000 | 7,999,000 | 7,305,000 | 8,386,000 | 8,463,000 | 7,789,000 | 7,811,000 | 6,636,000 | 5,528,000 | 5,135,000 | 4,044,000 | 3,802,000 | 3,468,000 | 2,961,000 | 3,591,000 | 3,528,000 | 2,612,000 | 1,889,000 | 2,256,543 | 2,837,392 | 2,418,355 | 1,655,342 | 1,237,122 | 996,437 | 852,744 | 745,774 | 1,384,398 | 1,103,432 | 119,647 | 517,892 |
| lease liability, current | 468,000 | 498,000 | 489,000 | 480,000 | 334,000 | 329,000 | 324,000 | 319,000 | 314,000 | 309,000 | 304,000 | 299,000 | 238,000 | 150,000 | 29,000 | 115,000 | 198,000 | 279,000 | 330,000 | 323,000 | 316,000 | 309,000 | 302,000 | 295,000 | 288,000 | 281,000 | ||||||||||||||||
| total current liabilities | 31,980,000 | 19,573,000 | 27,413,000 | 25,685,000 | 25,093,000 | 32,774,000 | 19,135,000 | 13,405,000 | 13,478,000 | 15,649,000 | 21,947,000 | 14,061,000 | 14,864,000 | 11,268,000 | 8,778,000 | 11,353,000 | 12,871,000 | 12,916,000 | 12,129,000 | 9,715,000 | 9,053,000 | 8,542,000 | 6,777,000 | 6,192,000 | 5,626,000 | 4,918,000 | 4,550,000 | 4,743,000 | 4,105,000 | 6,339,000 | 8,656,575 | 9,613,483 | 7,726,978 | 3,382,166 | 6,476,534 | 6,077,692 | 5,738,892 | 1,918,125 | 1,976,812 | 5,722,551 | 4,876,110 | 27,708,696 |
| lease liability, net of current portion | 410,000 | 502,000 | 630,000 | 755,000 | 766,000 | 852,000 | 936,000 | 1,018,000 | 1,100,000 | 1,181,000 | 1,260,000 | 1,337,000 | 1,414,000 | 1,490,000 | 29,000 | 115,000 | 198,000 | 279,000 | 360,000 | 438,000 | 513,000 | 588,000 | ||||||||||||||||||||
| total long-term liabilities | 410,000 | 502,000 | 630,000 | 755,000 | 766,000 | 852,000 | 936,000 | 1,018,000 | 1,100,000 | 1,181,000 | 1,260,000 | 1,337,000 | 1,414,000 | 1,490,000 | 29,000 | 115,000 | 198,000 | 279,000 | 360,000 | 438,000 | 513,000 | 588,000 | 12,000 | 6,054 | 4,224,354 | 16,307 | 20,476 | 24,646 | 5,069,038 | 4,737,293 | 19,149 | 2,899,669 | ||||||||||
| total liabilities | 32,390,000 | 20,075,000 | 28,043,000 | 26,440,000 | 25,859,000 | 33,626,000 | 20,071,000 | 14,423,000 | 14,578,000 | 16,830,000 | 23,207,000 | 15,398,000 | 16,278,000 | 12,758,000 | 8,778,000 | 11,353,000 | 12,871,000 | 12,916,000 | 12,158,000 | 9,830,000 | 9,251,000 | 8,821,000 | 7,137,000 | 6,630,000 | 6,139,000 | 5,506,000 | 4,562,000 | 4,743,000 | 4,105,000 | 6,339,000 | 8,656,575 | 9,613,483 | 7,733,032 | 7,606,520 | 6,492,841 | 6,098,168 | 5,763,538 | 6,987,163 | 6,714,105 | 5,741,700 | 4,876,110 | 30,608,365 |
| commitments and contingencies | ||||||||||||||||||||||||||||||||||||||||||
| stockholders’ equity: | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2025 and december 31, 2024; no shares issued and outstanding at june 30, 2025 and december 31, 2024 | ||||||||||||||||||||||||||||||||||||||||||
| common stock | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 358 | 285 | 277 | 239 | 208 | 199 | 193 | 97 | 97 | 98 | 98 | 60 |
| treasury stock | -6,795,000 | -6,795,000 | -6,795,000 | -6,795,000 | -6,795,000 | -6,795,000 | -6,795,000 | -5,121,000 | ||||||||||||||||||||||||||||||||||
| additional paid-in capital | 1,394,723,000 | 1,380,669,000 | 1,368,972,000 | 1,362,305,000 | 1,350,801,000 | 1,340,789,000 | 733,546,000 | 729,278,000 | 724,754,000 | 453,057,000 | 445,267,000 | 432,330,000 | 430,390,000 | 428,086,000 | 425,614,000 | 424,116,000 | 422,745,000 | 419,528,000 | 412,589,000 | 411,082,000 | 409,569,000 | 407,478,000 | 405,803,000 | 404,581,000 | 403,630,000 | 402,464,000 | 401,090,000 | 399,847,000 | 231,587,000 | 157,146,000 | 94,339,179 | 78,999,693 | 77,264,402 | 73,052,514 | 68,326,818 | 66,858,121 | 65,617,288 | 54,902,270 | 54,277,716 | 53,729,783 | 53,123,840 | 13,769 |
| accumulated deficit | -599,097,000 | -533,536,000 | -487,907,000 | -452,490,000 | -427,550,000 | -405,299,000 | -377,944,000 | -353,339,000 | -330,805,000 | -311,580,000 | -292,049,000 | -272,490,000 | -256,717,000 | -239,285,000 | -223,182,000 | -210,826,000 | -197,583,000 | -182,202,000 | -168,192,000 | -157,244,000 | -147,956,000 | -138,384,000 | -128,697,000 | -121,247,000 | -115,516,000 | -107,842,000 | -102,918,000 | -97,678,000 | -91,078,000 | -84,406,000 | -80,854,932 | -76,770,459 | -70,670,801 | -65,499,167 | -60,277,267 | -56,632,658 | -52,825,226 | -49,132,433 | -45,545,445 | -40,454,482 | -35,717,938 | -27,852,872 |
| accumulated other comprehensive loss | -166,000 | -216,000 | -788,000 | 1,632,000 | -2,272,000 | -1,599,000 | -389,000 | -905,000 | -1,040,000 | -618,000 | -1,761,000 | -1,649,000 | -1,411,000 | -549,000 | -170,000 | -189,000 | -104,000 | -49,000 | -423,000 | -117,000 | -147,000 | -109,000 | -19,769 | -3,558 | -5,999 | -7,499 | -6,892 | -6,137 | -6,786 | -195 | -7,370 | -4,848 | -12,461 | |||||||||
| total stockholders’ equity | 795,461,000 | 846,918,000 | 880,278,000 | 911,448,000 | 920,980,000 | 933,892,000 | 348,419,000 | 368,240,000 | 386,115,000 | 134,065,000 | 145,322,000 | 151,285,000 | 165,230,000 | 182,270,000 | 201,884,000 | 213,121,000 | 224,974,000 | 237,223,000 | 244,344,000 | 253,793,000 | 261,947,000 | 268,283,000 | 277,119,000 | 283,492,000 | 288,354,000 | 294,574,000 | 297,750,000 | 302,053,000 | 140,363,000 | 72,632,000 | 13,464,836 | 2,225,961 | 6,587,879 | 7,546,087 | 8,042,867 | 10,219,525 | 12,785,469 | 5,769,739 | 8,724,998 | 13,270,551 | 17,393,539 | |
| total liabilities and stockholders’ equity | 827,851,000 | 866,993,000 | 908,321,000 | 937,888,000 | 946,839,000 | 967,518,000 | 368,490,000 | 382,663,000 | 400,693,000 | 150,895,000 | 168,529,000 | 166,683,000 | 181,508,000 | 195,028,000 | 210,662,000 | 224,474,000 | 237,845,000 | 250,139,000 | 256,502,000 | 263,623,000 | 271,198,000 | 277,104,000 | 284,256,000 | 290,122,000 | 294,493,000 | 300,080,000 | 302,312,000 | 306,796,000 | 144,468,000 | 78,971,000 | 22,121,411 | 11,839,444 | 14,320,911 | 15,152,607 | 14,535,708 | 16,317,693 | 18,549,007 | 12,756,902 | 15,439,103 | 19,012,251 | ||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2025 and december 31, 2024; no shares issued and outstanding at march 31, 2025 and december 31, 2024 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2024 and 2023; no shares issued and outstanding at december 31, 2024 and 2023 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2024 and december 31, 2023; no shares issued and outstanding at september 30, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2024 and december 31, 2023; no shares issued and outstanding at june 30, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2024 and december 31, 2023; no shares issued and outstanding at march 31, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2023 and 2022; no shares issued and outstanding at december 31, 2023 and 2022 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2023 and december 31, 2022; no shares issued and outstanding at september 30, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2023 and december 31, 2022; no shares issued and outstanding at june 30, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2023 and december 31, 2022; no shares issued and outstanding at march 31, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||
| short-term investments – available for sale | 118,853,000 | 125,615,000 | 152,691,000 | 172,445,000 | 175,732,000 | 204,871,000 | 219,429,000 | 224,874,000 | 219,269,000 | 251,434,000 | 244,212,000 | 253,901,000 | 267,261,000 | 257,120,000 | 273,513,000 | 284,375,000 | 276,741,000 | 134,656,000 | 107,556,000 | 41,112,000 | 11,587,478 | 7,270,719 | 8,689,630 | 7,954,240 | 10,075,058 | 11,562,950 | 12,036,539 | 7,292,863 | 13,335,499 | 15,349,507 | 12,162,251 | |||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2022 and 2021; no shares issued and outstanding at december 31, 2022 and 2021 | ||||||||||||||||||||||||||||||||||||||||||
| accumulated other comprehensive income | -1,102,000 | -54,000 | -46,000 | 333,000 | -812,000 | 12,000 | 157,000 | 239,000 | ||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2022 and december 31, 2021; no shares issued and outstanding at september 30, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2022 and december 31, 2021; no shares issued and outstanding at june 30, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2022 and december 31, 2021; no shares issued and outstanding at march 31, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||
| deferred public offering and other financing costs | 76,000 | 48,000 | 68,000 | 89,000 | 99,000 | 128,000 | 173,000 | 90,000 | 120,000 | 150,000 | 180,000 | 210,000 | 240,000 | 269,613 | 275,029 | 17,568 | 439,349 | 521,538 | 614,380 | |||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2021 and 2020; no shares issued and outstanding at december 31, 2021 and 2020 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2021 and december 31, 2020; no shares issued and outstanding at september 30, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2021 and december 31, 2020; no shares issued and outstanding at june 30, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2021 and december 31, 2020; no shares issued and outstanding at march 31, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2020 and 2019; no shares issued and outstanding at december 31, 2020 and 2019 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2020 and december 31, 2019; no shares issued and outstanding at september 30, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2020 and december 31, 2019; no shares issued and outstanding at june 30, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2020 and december 31, 2019; no shares issued and outstanding at march 31, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||
| liabilities, convertible notes and stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||
| deferred rent | 12,000 | 6,054 | 10,862 | 16,307 | 20,476 | 24,646 | 27,624 | 31,239 | 19,149 | |||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2019 and 2018; no shares issued and outstanding at december 31, 2019 and 2018 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2019 and december 31, 2018; no shares issued and outstanding at september 30, 2019 and december 31, 2018 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2019 and december 31, 2018; no shares issued and outstanding at june 30, 2019 and december 31, 2018 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2019 and december 31, 2018; no shares issued and outstanding at march 31, 2019 and december 31, 2018 | ||||||||||||||||||||||||||||||||||||||||||
| accrued interest | 21,960 | 34,894 | 152,361 | 121,111 | 112,475 | |||||||||||||||||||||||||||||||||||||
| convertible notes payable, current portion | 3,450,540 | 3,269,582 | 1,911,024 | 1,670,509 | 310,350 | |||||||||||||||||||||||||||||||||||||
| debt conversion feature liability | 1,397,597 | 453,350 | 731,048 | 1,698,671 | 2,154,062 | 1,956,566 | 62,191 | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2018 and 2017; no shares issued and outstanding at december 31, 2018 and 2017 | ||||||||||||||||||||||||||||||||||||||||||
| accrued interest, current | 34,000 | 9,982 | 59,333 | 22,674 | 10,455 | |||||||||||||||||||||||||||||||||||||
| convertible notes payable, current | 3,721,000 | 3,180,411 | 3,050,427 | 2,826,135 | 2,382,688 | |||||||||||||||||||||||||||||||||||||
| debt conversion feature liability, current | 37,000 | 2,030,226 | 894,152 | 1,351,135 | 1,286,621 | |||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2018 and december 31, 2017; no shares issued and outstanding at september 30, 2018 and december 31, 2017 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2018 and december 31, 2017; no shares issued and outstanding at june 30, 2018 and december 31, 2017 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2018 and december 31, 2017; no shares issued and outstanding at march 31, 2018 and december 31, 2017 | ||||||||||||||||||||||||||||||||||||||||||
| prepaid clinical trial costs | 886,873 | 1,346,171 | 1,732,789 | 2,183,180 | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2017 and 2016; no shares issued and outstanding at december 31, 2017 and 2016 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2017 and december 31, 2016; no shares issued and outstanding at september 30, 2017 and december 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2017 and december 31, 2016; no shares issued and outstanding at june 30, 2017 and december 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||
| accrued interest, non-current | 47,113 | 202,882 | 183,611 | |||||||||||||||||||||||||||||||||||||||
| convertible notes payable | 3,713,029 | 3,139,861 | 2,151,540 | 1,429,993 | ||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2017 and december 31, 2016; no shares issued and outstanding at march 31, 2017 and december 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2016 and 2015; no shares issued and outstanding at december 31, 2016 and 2015 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at september 30, 2016 and december 31, 2015; no shares issued and outstanding at september 30, 2016 and december 31, 2015 | ||||||||||||||||||||||||||||||||||||||||||
| deferred public offering financing costs | 158,842 | 515,381 | 157,455 | |||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at june 30, 2016 and december 31, 2015; no shares issued and outstanding at june 30, 2016 and december 31, 2015 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at march 31, 2016 and december 31, 2015; no shares issued and outstanding at march 31, 2016 and december 31, 2015 | ||||||||||||||||||||||||||||||||||||||||||
| accrued license fees | 24,826,374 | |||||||||||||||||||||||||||||||||||||||||
| stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.00001 par value: 10,000,000 shares authorized at december 31, 2015 and no shares authorized at december 31, 2014; no shares issued and outstanding at december 31, 2015 and 2014 | ||||||||||||||||||||||||||||||||||||||||||
| deferred ipo financing costs | 2,408,149 | |||||||||||||||||||||||||||||||||||||||||
| other assets | 80,000 | 775 | ||||||||||||||||||||||||||||||||||||||||
| total liabilities and stockholders’ deficit | 22,269,649 | 2,769,322 | ||||||||||||||||||||||||||||||||||||||||
| cash | 327,007 | |||||||||||||||||||||||||||||||||||||||||
| liabilities, convertible notes and stockholders’ deficit | ||||||||||||||||||||||||||||||||||||||||||
| stockholders’ deficit: | ||||||||||||||||||||||||||||||||||||||||||
| total stockholders’ deficit | -27,839,043 | |||||||||||||||||||||||||||||||||||||||||
| revenues | ||||||||||||||||||||||||||||||||||||||||||
| operating expenses: | ||||||||||||||||||||||||||||||||||||||||||
| research and development | 138,969 | |||||||||||||||||||||||||||||||||||||||||
| general and administrative | 322,071 | |||||||||||||||||||||||||||||||||||||||||
| total operating expenses | 461,040 | |||||||||||||||||||||||||||||||||||||||||
| income from operations | -461,040 | |||||||||||||||||||||||||||||||||||||||||
| other incomes: | ||||||||||||||||||||||||||||||||||||||||||
| change in fair value of accrued license fees | 4,960,511 | |||||||||||||||||||||||||||||||||||||||||
| change in fair value of debt conversion feature liability | 82,656 | |||||||||||||||||||||||||||||||||||||||||
| amortization of debt discount | 171,955 | |||||||||||||||||||||||||||||||||||||||||
| interest expense | 35,253 | |||||||||||||||||||||||||||||||||||||||||
| total other incomes | 5,250,375 | |||||||||||||||||||||||||||||||||||||||||
| net income | -5,711,415 | |||||||||||||||||||||||||||||||||||||||||
| basic and diluted net income per share | -1.4 | |||||||||||||||||||||||||||||||||||||||||
| weighted-average shares used for eps calculation | 4,073,609 |
We provide you with 20 years of balance sheets for Viking Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Viking Therapeutics. Explore the full financial landscape of Viking Therapeutics stock with our expertly curated balance sheets.
The information provided in this report about Viking Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.